Where Unmet Needs
Meet Smart Science
Furthering scientific discovery starts with
a passionate drive to solve the challenges
others believe are impossible.
We are taking on the challenges of complex and debilitating conditions and are committed to meeting the needs of people suffering from serious and often life-threatening illnesses. Today, Tanabe Pharma Corporation group companies are focused on driving scientific discovery in many areas, including diseases like Parkinson's disease (PD), Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP).
PD affects 10 million people worldwide
The second most common neurodegenerative disease in the elderly behind Alzheimer’s, PD affects 10 million people worldwide, yet there’s still no cure. The condition presents with significant morbidity and disability and involves both motor impairments, such as tremors, walking difficulties and postural imbalance, and non-motor impairments, such as sleeping disorders, mood disturbances, anxiety and depression. In some cases, psychotic symptoms can occur. We will not rest until strides are made to improve quality of life for people living with this neurodegenerative disease.
Scientific progress for a progressive (and difficult-to-diagnose) condition
Always looking to the future, we have begun to explore new potential treatment options that we hope will help control the difficult symptoms and motor fluctuations associated with Parkinson’s disease. We hope the new data from our expanding CNS portfolio will provide further understanding and better treatment of this disease.
In addition to our scientific research in the space, we’re committed to educating patients on how to communicate their symptoms to HCPs. Staying abreast of the correct terminology, how the disease progresses and movement-related symptoms (motor fluctuations) can put patients on the path to better care. It’s time we all became “fluent” in Parkinson’s.
Tanabe Pharma America is driving discovery every day through smart science with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases.
Our Global Pipeline
Clinical trials are a fundamental part of clinical research and help answer key questions in health care and drug development.
TPA contributes to a deeper understanding of complex diseases by sharing findings with the scientific community.
Read Moredoi:10.1016/j.eclinm.2022.101590
doi:10.1002/mus.26740
[clinical trial NCT01492686]
doi:10.1371/journal.pone.0258614
doi:10.1002/mus.27467
doi:10.1136/jnnp-2020-323271
We developed our IITs Program in order to provide support for Investigator-Initiated clinical research or Health Economics Outcome Independent Research that illustrates the potential to foster knowledge and understanding of TPA's product(s). This program is integral to driving scientific and clinical knowledge and improving quality of life and care for patients.
Registration of Clinical Trial Information and Disclosure of Results
a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries
TPA will register and disclose information on publicly accessible clinical trial registries such as ClinicalTrials.gov regarding clinical trials that are being conducted or have been conducted.
b. Disclosure of clinical trial summary results
TPA will disclose the results from clinical trials in patients that form part of the submission package for products approved in the United States. Results will not be disclosed if TPA decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:
- A third party, such as a company involved in joint development, has not agreed to disclosure.
- Disclosure may interfere with publication in medical journals.
- Disclosure may interfere with the protection of intellectual property rights.